Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
165.3 USD | +0.39% | +2.00% | +6.81% |
02:44pm | Deutsche Bank Raises AbbVie's Price Target to $175 Form $170 | MT |
02:27pm | Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 29.68 and 24.37 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.81% | 292B | C+ | ||
+26.14% | 672B | C+ | ||
+24.17% | 550B | B | ||
-6.63% | 351B | C+ | ||
+14.82% | 317B | B- | ||
+2.98% | 211B | B+ | ||
+0.21% | 203B | B- | ||
-11.32% | 144B | C+ | ||
-7.95% | 141B | C+ | ||
-3.43% | 113B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ABBV Stock
- Ratings AbbVie Inc.